Zacks Investment Research downgraded shares of Catasys (NASDAQ:CATS) from a hold rating to a sell rating in a research note published on Thursday morning.
According to Zacks, “Catasys, Inc., formerly known as Hythiam, Inc., provides specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Company’s program seeks to improve member health by delivering medical and psychosocial interventions in combination with long term care coaching, including their proprietary treatment program for alcoholism and stimulant dependence. Catasys, Inc. is based in Los Angeles. “
Catasys (NASDAQ:CATS) traded down $0.19 during trading hours on Thursday, hitting $4.69. 42,144 shares of the stock were exchanged, compared to its average volume of 75,295. Catasys has a twelve month low of $3.30 and a twelve month high of $14.00.
A hedge fund recently bought a new stake in Catasys stock. Weber Alan W acquired a new stake in Catasys, Inc. (NASDAQ:CATS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 108,165 shares of the company’s stock, valued at approximately $406,000. Weber Alan W owned about 0.68% of Catasys at the end of the most recent reporting period. Institutional investors and hedge funds own 4.68% of the company’s stock.
Catasys Company Profile
Catasys, Inc provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The companys OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter.